In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.
While the last several decades saw a lack of progress in treatment outcomes in this setting, the outlook has recently changed dramatically, driven by a deepening understanding of melanoma biology and host immunology.
Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where thew new agent pidilizumab fits into the picture.
Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs— ipilimumab (Yervoy) and vemurafenib (Zelboraf)—for the treatment of metastatic melanoma.
When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.